Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Haploidentical Hematopoietic Stem Cell Transplantation Clinical Trial

Official title: Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide

Status Recruiting

Clinical Trial Summary

Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.

Clinical Trial Description

Hematopoietic stem cell transplantation from a haploidentical donor (haplo-HCT) are increasingly used in patients lacking a matched donor, but the optimal strategy needs to be defined. This study aims to investigate the outcome of haplo-HCT with early antithymocyte globulin and low dose posttransplant cyclophosphamide (ATG/LD-PTCy) in a single center. ;

Related Conditions & MeSH terms

• Haploidentical Hematopoietic Stem Cell Transplantation

• NCT number: NCT06041893
• Study type: Observational [Patient Registry]
• Source: Samsung Medical Center
• Contact: Hee Young Ju
• Phone: 82-02-3410-0865
• Email: hyju320@gmail.com
• Status: Recruiting
• Start date: May 29, 2023
• Completion date: December 31, 2025